IRIS PubliCatt

E

Ruggeri, M., Rolli, F., Kondili, L., Nappi, C., Cicchetti, A., Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy ., <<EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH>>, 3; 2019 (19): 363-374. [doi:10.1080/14737167.2019.1537784] [http://hdl.handle.net/10807/135548]

Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .

Ruggeri, M
;Cicchetti, A.
2019

Abstract

E
2019
Inglese
Ruggeri, M., Rolli, F., Kondili, L., Nappi, C., Cicchetti, A., Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy ., <<EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH>>, 3; 2019 (19): 363-374. [doi:10.1080/14737167.2019.1537784] [http://hdl.handle.net/10807/135548]
Articolo in rivista, Nota a sentenza
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/135548
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact